Caplin Point sets Sep 18 record date; FY26 dividend ₹4

Key developments from recent disclosures

Caplin Point Laboratories Limited (CAPLIPOINT) has fixed September 18, 2026 as the record date for its 35th Annual General Meeting (AGM) and for determining eligibility for the final dividend for FY2025-26, if declared. The company communicated the record-date details to both BSE and NSE under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Separately, the company also disclosed the completion of an unannounced USFDA inspection at a facility of Caplin Steriles Limited, its subsidiary.

Alongside these corporate actions, Caplin Point also made disclosures linked to investor communication, including an audio recording of its earnings call for the quarter ended June 30, 2026 under Regulation 30. The cluster of filings matters for shareholders because it lays out the calendar for voting and dividend eligibility and provides signals around regulatory engagement at a key subsidiary.

Record date and AGM schedule

The company has scheduled its 35th AGM for September 25, 2026. It has set Friday, September 18, 2026 as the record date, which determines which shareholders are eligible to participate in the AGM and vote on resolutions. The record date also establishes eligibility for receiving any final dividend declared for FY2025-26.

Caplin Point stated that shareholders must hold equity shares (face value ₹2 each) as of the close of business on the record date to participate and vote. The announcement was made pursuant to Regulation 42 of the SEBI LODR Regulations, 2015. The company also issued a newspaper publication for convening the 35th AGM through video conferencing.

Board meeting timeline behind the record date

The record date and AGM timeline were approved by the Board of Directors during a meeting held on August 12, 2026, as per the disclosed schedule. The same board meeting was slated to consider unaudited financial results for the quarter ended June 30, 2026, recommend a final dividend for FY2025-26, convene the AGM, and fix the record date for the dividend.

The company also stated that the trading window for insiders would be closed from July 1, 2026 to August 14, 2026. For investors tracking governance and compliance, these dates provide clarity on the company’s process around results, dividend recommendation, and shareholder meetings.

Final dividend recommendation: ₹4 per share

Caplin Point’s board recommended a final dividend of ₹4 per equity share (200%) on equity shares of face value ₹2 each for FY2025-26. The company’s disclosures also refer to a final dividend per share of ₹4.00.

The record date of September 18, 2026 is the cut-off for eligibility for this final dividend, if declared. Investors typically track this date closely, since shareholding as of the record date determines entitlement.

Completion of unannounced USFDA inspection at Caplin Steriles

Caplin Point disclosed the completion of an unannounced USFDA inspection at a facility of Caplin Steriles Limited, which is the company’s subsidiary. The disclosure indicates the inspection has been completed. No additional inspection details were provided in the supplied text.

For pharmaceutical manufacturers, USFDA inspections are a critical compliance checkpoint for regulated-market operations. Investors generally watch for such updates because inspection outcomes can influence operations, timelines, and regulatory standing for export-oriented facilities.

Investor communication: earnings call audio for quarter ended June 30, 2026

The company also disclosed, under Regulation 30 (LODR), an “Analyst / Investor Meet - Outcome” item referencing the audio recording of the earnings call for the quarter ended June 30, 2026. This provides an additional information channel for shareholders and analysts reviewing management commentary on operating performance and business conditions.

While the supplied text does not include the contents of the call, the disclosure confirms the availability of the audio record tied to the June 2026 quarter.

Financial performance snapshot from recent results

Caplin Point’s Q1FY27 results showed revenue from operations of ₹610.36 crore, up 19.63% year-on-year from ₹510.22 crore in Q1FY26. On a quarter-on-quarter basis, revenue rose 1.70% from ₹600.16 crore in Q4FY26.

EBITDA for Q1FY27 was reported at ₹247.03 crore, up 22.96% year-on-year from ₹200.90 crore and up 6.20% quarter-on-quarter from ₹232.60 crore. The company’s FY26 revenue from operations was disclosed at ₹2,187.19 crore, up 12.9% year-on-year from ₹1,937.47 crore in FY25.

Stock and company data points cited

The supplied text contains multiple share-price references for Caplin Point on September 3, 2026, including ₹2,720 (as on 03 September, 2026 | 02:09) and ₹2,824.60 (as on 3rd September 2026). It also cites a market capitalisation of ₹19,465.08 crore as of September 3, 2026, and a current dividend yield of 0.16.

Caplin Point Laboratories Ltd., incorporated in 1990, is described as operating in the pharmaceuticals sector. The parent and listed entity is headquartered in Chennai and is listed on BSE and NSE.

Summary table: dates, dividend, and key figures

Market impact and what investors can track next

The immediate market relevance of the record date is straightforward: shareholders must hold shares by the close of business on September 18, 2026 to be eligible to vote at the AGM and to receive the final dividend for FY2025-26, if declared. The dividend recommendation of ₹4 per share sets a concrete expectation for the proposal that will go to shareholders.

The USFDA inspection disclosure is a separate regulatory datapoint around Caplin Steriles, the subsidiary. With only the completion stated in the supplied text, investors will typically watch for any subsequent regulatory communications that may add detail.

Conclusion

Caplin Point’s latest disclosures set the calendar for shareholder participation with a September 18, 2026 record date and a September 25, 2026 AGM, while also reiterating a ₹4 final dividend recommendation for FY2025-26. The company also flagged the completion of an unannounced USFDA inspection at Caplin Steriles and made available the earnings call audio for the quarter ended June 30, 2026.